Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) announced its earnings results on Thursday. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.36, Zacks reports. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The company had revenue of $8.75 million during the quarter, compared to analyst estimates of $10.98 million.
Entrada Therapeutics Trading Down 1.4%
Shares of Entrada Therapeutics stock traded down $0.12 during trading hours on Tuesday, reaching $8.70. 78,713 shares of the company's stock were exchanged, compared to its average volume of 128,417. The stock has a market cap of $330.19 million, a P/E ratio of 5.47 and a beta of 0.04. The company has a 50 day moving average of $9.13 and a two-hundred day moving average of $13.65. Entrada Therapeutics has a fifty-two week low of $7.10 and a fifty-two week high of $21.79.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Monday, March 31st.
Get Our Latest Stock Analysis on TRDA
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Articles
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
